>
Thimble Point Acquisition logo

THMAU - Thimble Point Acquisition Share Price

$9.9 0.0  0.0%

Sector
Healthcare
Size
Market Cap £n/a
Enterprise Value £n/a
Revenue £n/a
Position in Universe th / 7408
Bullish
Bearish
Unlock THMAU Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 01st Jan 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
0.000 0.000 0.000 0.000 0.000 0.000
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the nine months ended 30 September 2021, PearTherapeutics Inc revenues was not reported. Net losstotaled to $1.5M.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

THMAU Revenue Unlock THMAU Revenue

Net Income

THMAU Net Income Unlock THMAU Revenue

Normalised EPS

THMAU Normalised EPS Unlock THMAU Revenue

PE Ratio Range

THMAU PE Ratio Range Unlock THMAU Revenue

Dividend Yield Range

THMAU Dividend Yield Range Unlock THMAU Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2022
31st Dec 2023
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
THMAU EPS Forecasts Unlock THMAU Revenue
Profile Summary

Pear Therapeutics, Inc., formerly Thimble Point Acquisition Corp., is a commercial-stage healthcare company. The Company is engaged in developing a new class of software-based medicines that is referred to as prescription digital therapeutics (PDTs), which use software to treat diseases. Its products include reset, reSET-O and Somryst. Its reset product is indicated for the treatment of substance use disorder (SUD) as a monotherapy. Its reSET-O product is developed for treatment of opioid use disorder (OUD) in combination with buprenorphine. Its Somryst product is the only software-based and guideline-recommended treatment for chronic insomnia. The Company’s pipeline consists of 14 product candidates, including candidates in psychiatry, neurology, and outside of central nervous system therapeutic areas such as gastrointestinal (GI), oncology, and cardiovascular. It focuses on psychiatric and neurologic conditions, which supports its strategy to commercialize its own products.

Directors
Last Annual January 1st, 1970
Last Interim January 1st, 1970
No. of Shareholders: n/a
No. of Employees: n/a
Sector Healthcare
Industry Biotechnology & Medical Research
Index
Exchange NASDAQ Capital Market
Shares in Issue
Free Float (0.0%)
Eligible for
× ISAs
SIPPs
THMAU Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Similar to THMAU
© Stockopedia 2022, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.